Pacific Edge Ltd is a NewZealand based company involved in developing and commercializing diagnostic and prognostic tools for the early detection and management of cancers... Show more
PFGTF saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on July 25, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 22 instances where the indicator turned negative. In of the 22 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
The Momentum Indicator moved below the 0 level on July 25, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on PFGTF as a result. In of 30 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
PFGTF moved below its 50-day moving average on July 25, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for PFGTF crossed bearishly below the 50-day moving average on July 25, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.272) is normal, around the industry mean (24.694). P/E Ratio (0.000) is within average values for comparable stocks, (77.706). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (4.425) is also within normal values, averaging (43.573).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PFGTF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFGTF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
Industry MedicalSpecialties
A.I.dvisor tells us that PFGTF and RSLS have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PFGTF and RSLS's prices will move in lockstep.
Ticker / NAME | Correlation To PFGTF | 1D Price Change % | ||
---|---|---|---|---|
PFGTF | 100% | -64.85% | ||
RSLS - PFGTF | 29% Poorly correlated | -9.16% | ||
FDMDF - PFGTF | 28% Poorly correlated | N/A | ||
RCEL - PFGTF | 26% Poorly correlated | -3.51% | ||
LIVN - PFGTF | 25% Poorly correlated | +0.88% | ||
MYGN - PFGTF | 20% Poorly correlated | -4.30% | ||
More |